|
WO2016094873A2
|
|
Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
|
|
WO2015116729A2
|
|
Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
|
|
WO2014151438A1
|
|
Multispecific anti-cd37 antibodies and related compositions and methods
|
|
AU2014200661A1
|
|
Single-chain multivalent binding proteins with effector function
|
|
AU2013205305A1
|
|
CD37 immunotherapeutic combination therapies and uses thereof
|
|
AU2013201195A1
|
|
A method for increasing antibody-dependent cytotoxicity with castanospermine
|
|
WO2013075027A2
|
|
Anti-sil6xr complex binding domains and methods of use
|
|
CN102958942A
|
|
Heterodimer binding proteins and uses thereof
|
|
EP2516467A2
|
|
Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
|
|
NZ620326A
|
|
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
NZ602407A
|
|
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
KR20110074900A
|
|
Tcr complex immunotherapeutics
|
|
CA2732574A1
|
|
Multi-specific binding proteins targeting b cell disorders
|
|
NZ590667A
|
|
Tgf-b antagonist multi-target binding proteins
|
|
US2011152173A1
|
|
TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
|
|
BRPI0913991A2
|
|
il6 immunotherapy
|
|
BRPI0914119A2
|
|
tgf-b multi-target binding protein antagonist
|
|
NZ612319A
|
|
Single-chain multivalent binding proteins with effector function
|
|
NZ606294A
|
|
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
